| BIOV Stock | | | ILS 26.20 0.90 3.56% |
President
Ms. Inbal Shmula Hillel was named Vice President Operations at BioView Ltd. effective January 28, 2014. Prior to this role, she served as Operations Manager at the company. Ms. Shmula Hillel previous work experience also includes an Operations Manager position at Exalenz Bioscience Ltd. for three years and a Supply Chain Manager position at Top Spin Medical Ltd. for two years since 2014.
| Age | 47 |
| Tenure | 10 years |
| Phone | 972 73 227 1025 |
| Web | https://www.bioview.com |
Shmula Hillel holds a Bachelors degree in Business Administration from Rupin College and a Masters degree in Industrial Management from Bar Ilan University.
Bio View Management Efficiency
Bio View's management efficiency ratios could be used to measure how well Bio View manages its routine affairs as well as how well it operates its assets and liabilities.
Bio View has accumulated 2.57
M in total debt with debt to equity ratio
(D/E) of 11.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bio View has a current ratio of 2.1, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Bio View until it has trouble settling it off, either with new capital or with free cash flow. So, Bio View's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio View sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio View's use of debt, we should always consider it together with cash and equity.
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel. Bio View (BIOV) is traded on Tel Aviv Stock Exchange in Israel and employs 35 people.
Management Performance
Bio View Leadership Team
Elected by the shareholders, the Bio View's board of directors comprises two types of representatives: Bio View inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio View's management team and ensure that shareholders' interests are well served. Bio View's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio View's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio View a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Bio Stock
Bio View financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio View security.